CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

Wedbush Raises Price Target on Hemab Therapeutics to $55 From $42, Keeps Outperform Rating

Positive
AI Analysis

Summary

Wedbush raised its price target on Hemab Therapeutics to $55 from $42 while maintaining an Outperform rating.

Importance:2/10
Sentiment:
0.60
price_target_increaseanalyst_rating
Related Companies

Read the original article

Published by yahoo_finance on July 13, 2026 10:54 AM

Read Original